AIRLINK 184.50 Decreased By ▼ -0.69 (-0.37%)
BOP 9.67 Decreased By ▼ -0.26 (-2.62%)
CNERGY 7.27 Decreased By ▼ -0.02 (-0.27%)
FCCL 36.99 Increased By ▲ 0.35 (0.96%)
FFL 14.47 Decreased By ▼ -0.06 (-0.41%)
FLYNG 24.71 Decreased By ▼ -0.21 (-0.84%)
HUBC 126.50 Decreased By ▼ -0.33 (-0.26%)
HUMNL 12.78 Decreased By ▼ -0.29 (-2.22%)
KEL 4.32 No Change ▼ 0.00 (0%)
KOSM 5.94 Decreased By ▼ -0.12 (-1.98%)
MLCF 42.63 Decreased By ▼ -0.26 (-0.61%)
OGDC 198.80 Increased By ▲ 3.36 (1.72%)
PACE 6.19 Decreased By ▼ -0.10 (-1.59%)
PAEL 38.25 Increased By ▲ 0.29 (0.76%)
PIAHCLA 17.03 Increased By ▲ 0.13 (0.77%)
PIBTL 7.76 Decreased By ▼ -0.03 (-0.39%)
POWER 9.30 Decreased By ▼ -0.09 (-0.96%)
PPL 169.11 Increased By ▲ 1.22 (0.73%)
PRL 33.30 Decreased By ▼ -0.72 (-2.12%)
PTC 22.75 Increased By ▲ 0.24 (1.07%)
SEARL 102.25 Decreased By ▼ -1.72 (-1.65%)
SILK 1.07 Decreased By ▼ -0.12 (-10.08%)
SSGC 35.95 No Change ▼ 0.00 (0%)
SYM 17.89 Decreased By ▼ -0.21 (-1.16%)
TELE 8.04 Increased By ▲ 0.02 (0.25%)
TPLP 11.72 Increased By ▲ 0.09 (0.77%)
TRG 66.21 Increased By ▲ 0.05 (0.08%)
WAVESAPP 12.10 Decreased By ▼ -0.03 (-0.25%)
WTL 1.55 Increased By ▲ 0.03 (1.97%)
YOUW 3.80 Decreased By ▼ -0.01 (-0.26%)
BR100 11,591 Increased By 21.2 (0.18%)
BR30 34,132 Increased By 98.2 (0.29%)
KSE100 110,624 Increased By 323.1 (0.29%)
KSE30 34,509 Increased By 122.6 (0.36%)

LONDON: Britain will start rolling out Pfizer's COVID-19 pill to vulnerable people next month, the health ministry said on Friday, targeting the treatment at people with compromised immune systems for whom the vaccine can be less effective.

The health ministry said that Pfizer's antiviral treatment Paxlovid, a combination of Pfizer's pill with an older antiviral ritonavir, will be made available to thousands of people from Feb. 10.

"It is fantastic news that this new treatment, the latest cutting-edge drug that the NHS is rolling out through new COVID-19 medicine delivery units, will now be available to help those at highest risk of COVID-19," National Health Service medical director Stephen Powis said.

Britain approves Pfizer's antiviral COVID-19 pill

"Trials have shown it can reduce hospitalisation and risk of death by 88%, meaning we'll be in the best position to save thousands of lives."

Britain has ordered 2.75 million courses of Paxlovid, and the government said that it would set out further details on access to the treatment soon but that people who are immunocompromised, cancer patients or those with Down's Syndrome could be able to access it directly.

Merck's COVID-19 pill active against Omicron in lab studies

It is the second antiviral being rolled out in Britain after molnupiravir, a pill made by Merck and Ridgeback Biotherapeutics which is being deployed to patients through the Panoramic trial.

Comments

Comments are closed.